0001642375
false
0001642375
2023-09-21
2023-09-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 21, 2023
GUARDION
HEALTH SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38861 |
|
47-4428421 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
2925
Richmond Avenue, Suite 1200
Houston,
Texas 77098
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (800) 873-5141
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
GHSI |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
September 21, 2023 (the “Effective Date”), Guardion Health Sciences, Inc. (the “Company”) entered into an employment
agreement (the “Employment Agreement”), with its Chief Accounting Officer, Katie Cox. The term of the Employment Agreement
will commence on the Effective Date and will continue until terminated by either party for any reason. Pursuant to the Employment Agreement,
Ms. Cox shall receive an annual base salary of $225,000, (the “Base Salary”), subject to withholding, and payable in accordance
with the Company’s regular payroll practices. Ms. Cox will be eligible to receive a bonus on an annual basis, which shall be awarded
in the sole discretion of the Company’s board of directors, and shall be eligible to participate in any bonus program adopted by
the Company for similarly situated employees.
In
addition, Ms. Cox will be eligible to participate in such retirement, life insurance, fringe and other employee benefit plans that the
Company maintains for its full-time employees (collectively, the “Benefits”), and shall be eligible to be reimbursed for
reasonable documented business expenses. Furthermore, any compensation paid to Ms. Cox will be subject to clawback as may be required
by law or otherwise.
In
the event Ms. Cox terminates her employment for Good Reason (as defined in the Employment Agreement), or the Company terminates her employment
without Cause (as defined in the Employment Agreement), including due to a Change in Control (as defined in the Employment Agreement),
Ms. Cox will be entitled to severance in the form of three (3) months of Base Salary and continuation of Benefits, payable in accordance
with the Company’s normal payroll practices, with the first payment commencing within 45 days of the termination date.
The
foregoing description of the Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by,
reference to the full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by
reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
GUARDION
HEALTH SCIENCES, INC. |
Date:
September 26, 2023 |
|
|
|
By: |
/s/
Jan Hall |
|
Name: |
Jan
Hall |
|
Title: |
President
and Chief Executive Officer |
Exhibit
10.1
EMPLOYMENT
AGREEMENT
This
Employment Agreement (this “Agreement”) is made by and between Guardion Health Sciences, Inc., a Delaware corporation
(the “Company”), and the individual identified on Exhibit A attached hereto (the “Employee”)
effective as of the Effective Date (as defined in Exhibit A).
RECITALS
WHEREAS,
the Company is a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods
and medical devices;
WHEREAS,
on July 25, 2023, Employee was promoted and named Chief Accounting Officer of the Company and her base salary was increased commensurate
with her promotion;
WHEREAS,
from and after the date hereof, the Company desires to continue to retain the services of the Employee pursuant to the terms and conditions
set forth herein and the Employee desires to be employed by the Company on such terms and conditions.
NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Employee
agree as follows:
AGREEMENT
1.
Term of Agreement. This Agreement will be effective on the Effective Date. The term of the Employee’s employment shall commence
on the Effective Date and continue until terminated pursuant to Section 5 of this Agreement. The entire period during which Employee
is employed by the Company pursuant to this Agreement is referred to herein as the “Term.”
2.
Position and Duties. During the Term, the Employee shall serve the Company in the position and perform the duties as are set forth
on Exhibit A attached hereto. Employee shall report to the Company’s President and Chief Executive Officer and to the Company’s
Board of Directors (the “Board”) or any committee thereof (the “Committee”).
3.
Full Business Time and Attention. Except as otherwise set forth in this Agreement, the Employee shall (a) devote all of Employee’s
business time, attention, skill and energy to the duties and responsibilities of Employee’s position (allowing for management of
Employee’s personal affairs that do not interfere with Employee’s duties and responsibilities to the Company); (b) service
the Company faithfully, diligently and to the best of Employee’s ability; (c) use Employee’s best reasonable efforts to promote
the success of the Company; and (d) cooperate fully with the Company’s Chief Executive Officer and the Board or the Committee in
the advancement of the Company’s best interests to assure full and efficient performance of Employee’s duties hereunder.
4.
Compensation and Benefits. During the Term:
a.
Base Salary. The Employee shall be paid the annual base salary set forth on Exhibit A attached hereto, or such greater
amount as may be determined by the Company from time to time in its sole discretion, payable in equal periodic installments according
to the Company’s customary payroll practices, but not less frequently than monthly (the “Base Salary”). The
Base Salary may be increased but not decreased without the Employee’s written consent.
b.
Bonus. Employee will be considered for a bonus on an annual basis. Whether and in what amount any bonus is awarded will be at
the sole discretion of the Board. In the event that the Company subsequently adopts a bonus program, Employee will be eligible to participate
in such bonus program and earn a bonus on the same basis as similarly situated employees of the Company.
c.
Benefits. The Employee shall, during the Term, be eligible to participate, commensurate with the Employee’s position, in
such retirement, life insurance, hospitalization, major medical, fringe and other employee benefit plans that the Company generally maintains
for its full-time employees (collectively, the “Benefits”). Notwithstanding the foregoing, the Company may discontinue
or terminate at any time any employee benefit plan, policy or program now existing or hereafter adopted and will not be required to compensate
the Employee for such discontinuance or termination; provided, however, that the Company shall be required to offer to the Employee any
rights or benefits extended to other employees in the event of termination of such plans or benefits, including, but not limited to,
coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”).
d.
Clawback. Notwithstanding any other provisions in this Agreement to the contrary, any compensation paid to the Employee pursuant
to this Agreement or any other agreement or arrangement with the Company which is subject to recovery under any law, government regulation,
or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such
law, government regulation, or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government
regulation or stock exchange listing requirement). However, Employee will not forfeit any compensation that is earned pursuant to this
Agreement.
e.
Reimbursement. If the Company is required to restate its publicly issued financial statements due to material non-compliance with
financial reporting requirements under federal securities laws, as a result of intentional misconduct committed by Employee, the Employee
will be required to reimburse the Company for any bonuses advanced to and profits received by Employee from sale of the Company’s
securities during the twelve (12) months subsequent to the initial issuance of such financial statements.
f.
Expenses. The Company shall pay on behalf of the Employee (or reimburse Employee for) reasonable documented expenses necessarily
incurred by Employee in the performance of Employee’s duties under this Agreement and in accordance with the Company’s existing
policies and procedures pertaining to the reimbursement of expenses to employees in general. Notwithstanding anything herein to the contrary
or otherwise, except to the extent any expense or reimbursement provided pursuant to this Section 4.e does not constitute a “deferral
of compensation” within the meaning of Section 409A of the Code (as defined below): (i) the amount of expenses eligible for reimbursement
provided to the Employee during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits
provided to the Employee in any other calendar year, (ii) the reimbursements for expenses for which the Employee is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred,
(iii) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit and
(iv) the reimbursements shall be made pursuant to objectively determinable and nondiscretionary Company policies and procedures regarding
such reimbursement of expenses.
5.
Termination of Employment.
a.
By the Company. The Company may terminate the Term and Employee’s employment, for the following reasons:
| i. | Death.
The Term shall terminate immediately upon the death of the Employee. |
| ii. | Disability.
The Company may terminate the Term and the Employee’s employment with the Company
immediately upon a determination of Disability. For purposes of this Agreement the Employee
has a “Disability” if, for physical or mental reasons, the Employee is unable
to perform the essential duties required of the Employee under this Agreement, even with
reasonable accommodations, for a period of six (6) consecutive months or a period of one-hundred
eighty (180) days during any twelve (12) month period, as determined by an independent medical
professional mutually acceptable to the parties. If requested by the Company, the Employee
shall submit to a reasonable number of examinations by the independent medical professional
making the determination of Disability at the Company’s expense. |
| iii. | For
Cause. The Company may terminate the Term and the Employee’s employment with the
Company at any time for Cause. For purposes of this Agreement, “Cause”
shall mean: (1) Employee’s conviction of or plea of guilty or nolo contendere to a
felony, or any other crime involving moral turpitude or which results in material harm to
the Company; (2) Employee’s fraud against the Company or any breach of fiduciary duty
owed to the Company; (3) Employee’s theft, misappropriation or embezzlement of the
assets or funds of the Company or any customer, or engagement in misconduct that is materially
injurious to the Company; (4) Employee’s gross negligence or willful misconduct in
the performance of Employee’s duties under this Agreement or Employee’s repeated
failure to perform his duties as instructed by the Company; (5) Employee’s material
breach of this Agreement, including any material violation of any of the restrictions set
forth in Section 7, or any Company policies, including the Company’s Code of Ethics,
which breach or violation, if capable of being cured, is not cured to the Board’s reasonable
satisfaction within ten (10) business days after written notice thereof to the Employee;
(6) Employee’s continuous failure to perform Employee’s assigned duties or responsibilities
(other than a failure resulting from Employee’s death or Disability as defined herein)
if such failure is not cured to the Board’s reasonable satisfaction within ten (10)
business days after written notice thereof to the Employee; (7) Employee’s knowing
violation of any federal or state law or regulation applicable to the Company’s business;
or (8) Employee’s commencement of alternative employment. |
| iv. | Without
Cause. The Company may terminate the Term and the Employee’s employment at any
time without Cause by providing the Employee with thirty (30) days’ prior written notice;
provided, that during such thirty (30) day notice period, the Company may, in its discretion,
place restrictions upon the Employee’s contact with the workplace, customers and other
business-related parties. |
b.
By Employee. The Employee may terminate the Term and Employee’s employment with the Company for any of the following reasons:
| i. | For
Any Reason. Upon thirty (30) days’ prior written notice delivered at any time,
the Employee may terminate the Term and Employee’s employment hereunder, for any reason
or no reason at all. |
For
Good Reason. The Employee may terminate the Term and Employee’s employment hereunder for “Good Reason” (as hereinafter
defined). For purposes of this Agreement, “Good Reason” shall mean any one of the conditions set forth below, so long
as (1) Employee has provided written notice to the Company of the existence of such condition within sixty (60) days of Employee’s
initial knowledge of its existence, (2) the Company has not remedied the condition caused by the occurrence within thirty (30) days of
such notice or such longer period as may be reasonably necessary, to the extent such condition is capable of being cured, and (3) the
Employee gives a notice of Employee’s termination of employment within thirty (30) days after the end of such thirty (30) day period
to remedy such condition, which notice must be given within the Initial Term. The following conditions will constitute “Good
Reason”: (A) a material diminution in the Employee’s duties, responsibilities or authority, except for any diminution
resulting from the Company’s retention of a chief financial officer; (B) a material breach by the Company of this Agreement or
any other material agreement with the Employee (e.g., an equity award); (C) the Company materially reduces the Employee’s Base
Salary, as in effect from time to time, without the Employee’s prior written consent; or (D) the Company directs the Employee to
participate in an unlawful act.
c.
Compensation Upon Termination.
|
i. |
Death. Within thirty
(30) days following the termination of the Term due to the Employee’s death, or such earlier time as may be required by law,
the Company shall pay to the Employee’s estate the Employee’s Base Salary and Benefits accrued through the date of the
Employee’s death. Upon payment to the Employee of the foregoing amounts, the Company shall have no further obligation or liability
to the Employee for duplicative payments or benefits under any other agreement, except as required by applicable law. |
|
ii. |
Disability. Within
thirty (30) days following the termination of the Term due to the Employee’s Disability, or such earlier time as may be required
by law, the Company shall pay to the Employee the Employee’s Base Salary and Benefits accrued through the date of the Employee’s
termination. Upon payment to the Employee of the foregoing amounts, the Company shall have no further obligation or liability to or
for the benefit of the Employee for duplicative payments or benefits under any other agreement, except as required by applicable law. |
|
iii. |
For Cause. Upon termination
of the Term for Cause, the Company shall pay to the Employee only the Employee’s Base Salary and Benefits accrued through the
date of the Employee’s termination. Upon payment to the Employee of the foregoing amounts, the Company shall have no further
obligation or liability to or for the benefit of the Employee for duplicative payments or benefits under any other agreement, except
as required by applicable law. |
|
iv. |
Without Cause, Including
Due to Change in Control. In the event that the Company terminates the Term and the Employee’s employment without Cause,
including if Employee’s employment is terminated following a Change in Control (as defined in Exhibit A) during this time
period, the Company shall pay or provide to the Employee: (1) three (3) months’ Base Salary and payment for continuation of Benefits,
and (2) Employee’s Base Salary and Benefits accrued through the date of the Employee’s termination. Subject to the conditions
precedent set forth herein, item (1) above shall be paid in accordance with the Company’s payroll practices in effect from time
to time, but Item (1) above shall be paid not less frequently than monthly. Upon payment to the Employee of the foregoing amounts,
the Company shall have no further obligation or liability to or for the benefit of the Employee for duplicative payments or benefits
under any other agreement, except as required by applicable law. |
|
v. |
For Any Reason. In
the event the Employee terminates employment with the Company during the Term for any reason other than Good Reason, the Company shall
pay to the Employee the Employee’s Base Salary and Benefits accrued through the date of the Employee’s termination. Upon
payment to the Employee of the foregoing amounts, the Company shall have no further obligation or liability to or for the benefit of
the Employee for duplicative payments or benefits under any other agreement, except as required by applicable law. |
|
vi. |
For Good Reason. If
the Employee terminates the Term and the Employee’s employment for Good Reason during the Initial Term, the Company shall pay
or provide to the Employee: (1) three (3) months’ Base Salary and payment for continuation of Benefits, and (2) the Employee’s
Base Salary and Benefits accrued through the date of termination. Subject to the conditions precedent set forth herein, item (1) above
shall be paid in accordance with the Company’s payroll practices in effect from time to time, but Item (1) above shall be paid
not less frequently than monthly. Upon payment to the Employee of the foregoing amounts, the Company shall have no duplicative obligation
or liability to or for the benefit of the Employee under any other agreement, except as required by applicable law. |
|
vii. |
Release. As an additional
prerequisite and condition precedent in order to be entitled to and receive the severance benefits described in Section 5(a)(iv) and
(vi) above (in excess of Base Salary and Benefits accrued through the date of termination), the Employee must execute, deliver to the
Company, and not revoke (to the extent the Employee is allowed to do so) a Release (as defined below) within forty-five (45) days of
the date of the Employee’s termination of employment (the “Release Period”). No severance benefits shall be
paid until after the effective date of the Release. “Release” shall mean a release of all claims that the Employee
has or may have against the Company, its Board, any of its subsidiaries or affiliates, or any of its employees, directors, officers,
employees, agents, plan sponsors, administrators, successors, fiduciaries, or attorneys, arising out of the Employee’s employment
with, and termination of employment from, the Company, except for any claims to enforce the terms of this Agreement and the then-applicable
terms of any other written agreement, plan or arrangement of the Company or any of its subsidiaries or affiliates, and any claims for
unemployment or workers’ compensation benefits by Employee. The Release shall not impose any additional restrictions on the Employee’s
post-employment activities, and shall be in a form that is otherwise reasonably acceptable to the Company or the Board. Notwithstanding
anything to the contrary in this Agreement, if the Release Period straddles two calendar years, no severance benefits shall be paid
to the Employee until the second calendar year (with any missed severance payments being paid to the Employee on the first payroll
date occurring in the second calendar year). |
6.
Indemnification and Insurance.
| a. | Indemnification.
The Employee shall be indemnified (and advanced expenses) to the fullest extent permitted
or authorized by the Certificate of Incorporation or Bylaws of the Company. |
| b. | D&O
Insurance. A directors’ and officers’ liability insurance policy (or policies)
shall be kept in place by the Company, during the Term providing coverage to the Employee
that is no less favorable to Employee in any respect (including, without limitation, with
respect to scope, exclusions, amounts and deductibles) than the coverage then being provided
to any other senior executives or directors of the Company. |
7.
Restrictive Covenants.
a. Confidentiality. The Employee acknowledges that the Confidential Information (as defined below) is a valuable, special, sensitive and unique asset of the business of the Company, the continued confidentiality of which is essential to the continuation of its business, and the improper disclosure or use of which could severely and irreparably damage the Company. The Employee agrees, for and on behalf of Employee, the Employee’s legal representatives, and the Employee’s successors and assigns that all Confidential Information is the property of the Company (and not of the Employee). The Employee further agrees that during the Term and at all times thereafter, the Employee (i) will continue to keep all Confidential Information strictly confidential and not disclose the Confidential Information to any other person or entity and (ii) shall not, directly or indirectly, disclose, communicate or divulge to any person, or use or cause or authorize any person to use any Confidential Information, except as may be used in the performance of the Employee’s duties hereunder in compliance with this Agreement and in the best interests of the Company. “Confidential Information” means all information, data and items relating to the Company (or any of its customers) which is valuable, confidential or proprietary, including, without limitation, information relating to the Company’s software, software code, accounts, receivables, customers and customer lists and data, prospective customers and prospective customer lists and data, Work Product, vendors and vendor lists and data, business methods and procedures, pricing techniques, business leads, budgets, memoranda, correspondence, designs, plans, schematics, patents, copyrights, equipment, tools, works of authorship, reports, records, processes, pricing, costs, products, services, margins, systems, software, service data, inventions, analyses, plans, intellectual property, trade secrets, manuals, training materials and methods, sales and marketing materials and compilations of and other items derived (in whole or in part) from the foregoing. Confidential Information may be in either paper, electronic or computer readable form. Notwithstanding the foregoing, “Confidential Information” shall not include information that: (i) becomes publicly known without breach of the Employee’s obligations under this Section 7(a), or (ii) is required to be disclosed by law or by court order or government order; provided, however, that if the Employee is required to disclose any Confidential Information pursuant to any law, court order or government order, (x) the Employee shall promptly notify the Company of any such requirement so that the Company may seek an appropriate protective order or waive compliance with the provisions of this Agreement, (y) the Employee shall reasonably cooperate with the Company to obtain such a protective order at the Company’s cost and expense, and (z) if such order is not obtained, or the Company waives compliance with the provisions of this Section 7(a), the Employee shall disclose only that portion of the Confidential Information which the Employee is advised by counsel that the Employee is legally required to so disclose. The Employee will notify the Company promptly and in writing of any circumstances of which the Employee has knowledge relating to any unauthorized possession or use of any Confidential Information by any Person.
b.
Immunity Notice. The Employee shall not be held criminally or civilly liable under any Federal or State trade secret law for the
disclosure of a trade secret or other Confidential Information that: (i) is made in confidence to a federal, state, or local government
official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected
violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under
seal. Should the Employee file a lawsuit against the Company for retaliation for reporting a suspected violation of law, the Employee
may disclose the trade secret or Confidential Information to the Employee’s attorney and use the trade secret or Confidential Information
in the court proceeding, if the Employee: (x) files any document containing the trade secret or Confidential Information under seal,
and (y) does not disclose the trade secret of Confidential, except pursuant to court order.
c.
Return of Company Property. The Employee will deliver to the Company at the termination of the Employee’s employment with
the Company, or at any other time the Company may request, all equipment, files, property, memoranda, notes, plans, records, reports,
computer tapes, printouts, Confidential Information, Work Product, software, documents and data (and all electronic, paper or other copies
thereof) belonging to the Company, which the Employee may then possess or have under the Employee’s control. However, nothing in
this Agreement or elsewhere shall prohibit the Employee from retaining (and using appropriately) copies of documents relating to Employee’s
personal rights and obligations.
d.
Intellectual Property Rights. The Employee acknowledges and agrees that all inventions, technology, processes, innovations, ideas,
improvements, developments, methods, designs, analyses, trademarks, service marks, and other indicia of origin, writings, audiovisual
works, concepts, drawings, reports and all similar, related, or derivative information or works (whether or not patentable or subject
to copyright), including but not limited to all patents, copyrights, copyright registrations, trademarks, and trademark registrations
in and to any of the foregoing, along with the right to practice, employ, exploit, use, develop, reproduce, copy, distribute copies,
publish, license, or create works derivative of any of the foregoing, and the right to choose not to do or permit any of the aforementioned
actions, which relate to the Company or its actual or anticipated business, research and development or existing or future products or
services and which are conceived, developed or made by the Employee while employed by the Company (collectively, the “Work Product”)
belong to the Company. All Work Product created by the Employee while employed by the Company (whether or not on the premises) will be
considered “work made for hire,” and as such, the Company is the sole owner of all rights, title, and interests therein.
All other rights to any new Work Product, including but not limited to all of the Employee’s rights to any copyrights or copyright
registrations related thereto, are hereby conveyed, assigned and transferred to the Company. The Employee will promptly disclose and
deliver such Work Product to the Company and, at the Company’s expense, perform all actions reasonably requested by the Company
(whether during or after the Term) to establish, confirm and protect such ownership (including, without limitation, the execution of
assignments, copyright registrations, consents, licenses, powers of attorney and other instruments).
e.
Non-Competition. While employed by the Company, the Employee shall not, directly or indirectly, enter into the employment of,
render any services to, engage, manage, operate, join, or own, or otherwise offer other assistance to or participate in, as an officer,
director, employee, principal, agent, proprietor, representative, stockholder, partner, associate, advisor or consultant, sole proprietor
or otherwise, any employer other than the Company. During the Term, Employee may own up to five percent (5%) of the outstanding stock
of a publicly held corporation which constitutes or is affiliated with an entity that is engaged in the Business only so long as the
Employee is not an officer, director, affiliate, employee, advisor or consultant, or otherwise maintains voting control or influence,
whether by shareholding, contract or otherwise, of such entity. For purposes of this Section 7, “Business” means the
business of the Company and its subsidiaries as described in the recitals to this Agreement, the actual business of the Company and its
subsidiaries as conducted as of the date of termination, and any anticipated business considered by the Board towards which the Company
or any subsidiaries thereof has taken material steps or incurred material expenditures in furtherance thereof prior to the termination
date and which is Employee is aware.
f.
Non-Solicitation. During the Term and for a period of one (1) year thereafter (the “Restricted Period”), the Employee
shall not, directly or indirectly, whether for the Employee’s own account or for the account of any other person, (i) attempt to
or solicit for hire any person who is employed by the Company or any of its subsidiaries, or solicit or attempt to solicit any such employee
to terminate employment with the Company or any of its subsidiaries, or (ii) endeavor to entice away from the Company, or otherwise interfere
with (whether by reason of cancellation, withdrawal, modification of relationship or otherwise), any actual or prospective relationship
of the Company or any of its subsidiaries, with respect to any person (x) who is employed by or otherwise engaged to perform services
for the Company or any of its subsidiaries, including, but not limited to, any independent contractor or representative or (y) who is
an actual or bona fide prospective licensee, landlord, or supplier of the Company or any of its subsidiaries (or other person with which
the Company or any of its subsidiaries had an actual or prospective bona fide business relationship). However, the Employee shall not
be deemed to be in violation of this Section 7 if Employee hires an individual who responds to a general, non-targeted advertisement
of employment.
g.
Non-Disparagement. The Employee agrees that the Employee will not make or publish any statement or communication which is false,
negative, unflattering or disparaging with respect to the Company or any of its respective affiliates and/or any of its respective direct
or indirect shareholders, officers, directors, members, managers, employees or agents. The foregoing shall not be violated by (i) statements
as required in response to legal proceedings or governmental investigations (including, without limitation, depositions in connection
with such proceedings), (ii) statements made in the context of prosecuting or defending any legal dispute (whether or not litigation
has commenced) as between the Employee on the one hand and the Company on the other, (iii) truthful information that is required or authorized
to be disclosed by applicable law or Company policy, and (iv) truthful internal statements and communications made during the Term as
part of Employee’s job duties. Moreover, nothing in this Agreement prevents Employee from (1) discussing or disclosing information
about unlawful acts in the workplace, such as harassment, discrimination, or any other conduct that Employee has reason to believe is
unlawful; (2) engaging in protected concerted activity or exercising Employee’s rights under the National Labor Relations Act;
or (3) providing truthful testimony or answers in response to any legal process, or during any judicial, quasi-judicial, or administrative
proceedings.
h.
Non-Interference with Employee’s Agency Rights. The Employee understands that the terms of this Agreement, including the
provisions regarding confidentiality and non- disparagement, are not intended to interfere with or waive any right (if any such right
otherwise existed) to file a charge, cooperate, testify or participate in an investigation with any appropriate federal or state governmental
agency, including the ability to communicate with such agency, such as, but not limited to, the Securities and Exchange Commission (“SEC”),
the Financial Industry Regulatory Authority (“FINRA”), any other securities regulatory agency or authority, or any
other self-regulatory organization, or any other federal or state regulatory authority (“Government Agencies”), whether
in connection with reporting a possible securities law violation or otherwise, without notice to Company. This Agreement further does
not limit the Employee’s right to receive a bounty or reward for information provided to any such Government Agencies, to the SEC
staff, or to any other securities regulatory agency or authority.
i.
Rationale for and Scope of Covenants. If any of the covenants contained in this Section 7 are held to be invalid or unenforceable
due to the unreasonableness of the time, geographic area, or range of activities covered by such covenants, such covenants shall nevertheless
be enforced to the maximum extent permitted by law and effective for such period of time, over such geographical area, or for such range
of activities as may be determined to be reasonable by a court of competent jurisdiction and the parties hereby consent and agree that
the scope of such covenants may be judicially modified, accordingly, in any proceeding brought to enforce such covenants. The Employee
agrees that the Employee’s services hereunder are of a special, unique, extraordinary and intellectual character and the Employee’s
position with the Company places the Employee in a position of confidence and trust with the customers, suppliers and employees of the
Company. The Employee and the Company agree that, in the course of employment hereunder, the Employee has and will continue to develop
a personal relationship with the Company’s customers, and a knowledge of these customers’ affairs and requirements as well
as confidential and proprietary information developed by the Company after the date of this Agreement. The Employee agrees that it is
reasonable and necessary for the protection of the goodwill, confidential and proprietary information, and legitimate business interests
of the Company that the Employee make the covenants contained herein, that the covenants are a material inducement for the Company to
employ or continue to employ the Employee and to enter into this Agreement. For the avoidance of doubt, for purposes of this Section
7, the term “Company” includes Guardion Health Sciences, Inc. and each of its other direct and indirect subsidiaries and
affiliates.
j.
Remedies.
| i. | The
Employee consents and agrees that if the Employee violates any covenants contained in this
Section 7, the Company would sustain irreparable harm and, therefore, in addition to any
other remedies which may be available to it, the Company shall be entitled to seek an injunction
restraining the Employee from committing or continuing any such violation of this Section
7. Nothing in this Agreement shall be construed as prohibiting the Company or the Employee
from pursuing any other remedies including, without limitation, recovery of damages. The
Employee acknowledges that Company’s direct and indirect subsidiaries are express third-party
beneficiaries of this Agreement and that they may each enforce these rights as a third-party
beneficiary. The Company has fully performed all obligations entitling it to the restrictive
covenants, and the restrictive covenants therefore are not executory or otherwise subject
to rejection and are enforceable under the United States Bankruptcy Code. However, if the
Company or its subsidiaries is in material breach of any obligation to the Employee under
this Agreement or any other material written agreement to which the Employee is a party,
the Restricted Period shall terminate if such breach is not cured to the Employee’s
reasonable satisfaction within ten (10) business days after the Employee provides the Company
with written notice of such breach. In the event of the breach by the Employee of any of
the provisions of this Section 7, the Company shall be entitled, in addition to all other
available rights and remedies, to terminate the Employee’s employment status hereunder.
The Company may assign the restrictive covenants set forth in this Section 7 in connection
with the acquisition of all or substantially all of the assets of the Company and its subsidiaries,
and any such assignee or successor shall be entitled to enforce the rights and remedies set
forth in this Section 7. The Employee acknowledges and agrees that the Restricted Period
for a violated provision of this Section 7 shall be tolled on a day-for-day basis for all
periods in which the Employee is found to have violated such provision so that the Company
receives the full benefit of the Restricted Period to which the Employee has agreed. |
| ii. | In
addition, and without limitation to the foregoing, except as required by law, if (A) the
Company files a civil action against the Employee based on the Employee’s alleged breach
of the Employee’s obligations under Section 7 hereof, and (B) a court of competent
jurisdiction issues a judgment that the Employee has breached any of such obligations and
has issued injunctive relief, then the Employee shall promptly repay to the Company any such
severance payments the Employee previously received pursuant to Section 5(c) in excess of
the Employee’s Base Salary and Benefits accrued through the date of the Employee’s
termination, and the Company will have no obligation to pay any of such excess amounts that
remain payable by the Company under Section 5.c. |
8.
Notice. Any notice required or desired to be given under this Agreement shall be in writing and shall be addressed as follows:
|
If
to Company: |
Via
email to: jhall@guardionhealth.com |
|
|
Attn:
Chief Executive Officer |
|
|
|
|
If
to Employee: |
Via
email to: kcox@guardionhealth.com |
|
|
Attn:
Katie Cox |
Notice
shall be deemed given on the date it is delivered via email. The address to which any notice must be sent may be changed by providing
written notice in accordance with this Section 8.
9.
General Provisions.
a.
Amendments. This Agreement (together with its Exhibits) contains the entire agreement between the parties regarding the subject
matter hereof. No agreements or representations, verbal or otherwise, express or implied, with respect to the subject matter of this
Agreement have been made by either party which are not set forth expressly in this Agreement. This Agreement may only be altered or amended
by the express mutual written consent of the Company and the Employee.
b.
Applicable Law. This Agreement shall be governed in accordance with the laws of the State of Delaware regardless of the conflict
of laws rules or statutes of any jurisdiction.
c.
Successors and Assigns. This Agreement will be binding upon the Employee’s heirs, executors, administrators or other legal
representatives or assigns. This Agreement will not be assignable by the Employee, but shall be assigned by the Company in connection
with the sale, lease, license, assignment, merger, consolidation, share exchange, liquidation, transfer, conveyance or other disposition
(whether direct or indirect) of all or substantially all of its business and/or assets in one or a series of related transactions (individually
and/or collectively, a “Fundamental Transaction”). The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the
Company under this Employment Agreement. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed
to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Employment Agreement
referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company
and shall assume all of the obligations of the Company under this Employment Agreement with the same effect as if such Successor Entity
had been named as the Company herein.
d.
No Waiver. The failure of any party to this Agreement to enforce at any time any of the provisions of this Agreement shall in
no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part thereof
or the right of any party under this Agreement to enforce each and every such provision. No waiver of any breach of this Agreement shall
be effective unless it is expressly acknowledged in a writing executed by the party against whom it is sought to be enforced, and any
such waiver shall not constitute a waiver of any other or subsequent breach.
e.
Section Headings, Construction. The headings used in this Agreement are provided for convenience only and shall not affect the
construction or interpretation of this Agreement. All words used in this Agreement shall be construed to be of such gender or number
as the circumstances require. In no event shall the terms or provisions hereof be construed against any party on the basis that such
party or counsel for such party drafted this Agreement or the attachments hereto.
f.
Severability. If any provision of this Agreement is held to be invalid or unenforceable by any court or arbitrator of competent
jurisdiction, such provision shall be severed from this Agreement, and the other provisions of this Agreement shall remain in full force
and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect
to the extent not held invalid or unenforceable.
g.
Survival. The provisions of Sections 5, 6, 7 and 9 of this Agreement shall survive the termination of the Term for any reason.
h.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original of this
Agreement, and all of which, when taken together, shall be deemed to constitute one and the same agreement. Signatures delivered electronically
(including, without limitation, by portable document format attached to an email) shall be effective for all purposes.
i.
Opportunity to Review. The Employee represents that the Employee has been provided with an opportunity to review the terms of
the Agreement with legal counsel.
j.
Compliance with Code Section 409A. This Agreement is intended, and shall be construed and interpreted, to comply with Section
409A of the Internal Revenue Code of 1986, as amended (the “Code”) or an exemption therefrom. For purposes of Code
Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation. Any amounts payable
solely on account of an involuntary termination shall be excludible from the requirements of Code Section 409A, either as separation
pay or as short-term deferrals to the maximum possible extent. Any reference to the Employee’s “termination,” “termination
of employment” or “termination of the Term” shall mean the Employee’s “separation from service” as
defined in Code Section 409A from the Company and all entities with whom the Company would be treated as a single employer for purposes
of Code Section 409A. Nothing herein shall be construed as a guarantee of any particular tax treatment to Employee and the Company shall
have no liability to the Employee with respect to any penalties that might be imposed on the Employee by Code Section 409A for any failure
of this Agreement to comply with Code Section 409A. In the event that the Employee is a “specified employee” (as described
in Code Section 409A), and any payment or benefit payable pursuant to this Agreement constitutes deferred compensation under Code Section
409A, then no such payment or benefit shall be made before the date that is six months after the Employee’s “separation from
service” (as described in Code Section 409A) (or, if earlier, the date of the Employee’s death). Any payment or benefit delayed
by reason of the immediately preceding sentence shall be paid out or provided in a single lump sum at the end of such required delay
period in order to catch up to the original payment schedule.
k.
Attorney’s Fees and Costs. In any action or proceeding (including any appeals) brought to enforce any provision of this
Agreement, each party shall be responsible for its own attorneys’ fees and costs; provided, however, that nothing herein precludes
the prevailing party in such an action from recovering its attorneys’ fees and costs in the manner and to the extent authorized
by applicable law and/or approved by a court of competent jurisdiction.
IN
WITNESS WHEREOF, the parties hereto, each of which is duly authorized to enter into this Agreement, have caused this Agreement to be
executed effective as of the Effective Date.
GUARDION
HEALTH SCIENCES, INC. |
|
KATIE
COX |
|
|
|
|
|
By:
|
/s/
Jan Hall |
|
|
/s/
Katie Cox |
Name:
|
Jan
Hall, Chief Executive Officer |
|
Date: |
September
21, 2023 |
|
|
|
|
|
Date:
|
September
21, 2023 |
|
|
|
EXHIBIT
A
| 1. | Effective
Date: September 21, 2023 |
| 2. | Employee
Name: Katie Cox |
| 3. | Position:
Chief Accounting Officer |
| 4. | Duties:
The Employee will have the duties and authorities customarily and ordinarily exercised
by executives holding the Chief Accounting Officer position at public entities of the Company’s
size and nature. Specifically, as Chief Accounting Officer, Employee will be responsible
for (i) leading and overseeing the Company’s accounting, financial, and SEC reporting
functions, and will be deemed the “principal financial officer” for regulatory
purposes until such time as the Company retains a chief financial officer, and (ii) such
other duties as may be assigned to Employee by the Chief Executive Officer or the Board from
time-to-time. |
| 5. | Location
of Employment: Employee’s home, currently located at [ ]. Employee acknowledges
and agrees that the Company may require Employee to attend physical meetings at various locations
from time-to-time, including in California. |
| 6. | Base
Salary: $225,000 per annum. |
| 7. | Change
in Control: “Change in Control” means in summary, the first to occur
of the following events: (i) a person or entity becomes the beneficial owner of more than
50% of the Company’s voting power; (ii) an unapproved change in the majority membership
of the Company’s Board; (iii) a merger or consolidation of the Company or any of its
subsidiaries, other than (A) a merger or consolidation that results in the Company’s
voting securities continuing to represent 50% or more of the combined voting power of the
surviving entity or its parent and the Company’s Board immediately prior to the merger
or consolidation continuing to represent at least a majority of the board of directors of
the surviving entity or its parent or (B) a merger or consolidation effected to implement
a recapitalization in which no person is or becomes the owner of the Company’s voting
securities representing more than 50% of the Company’s combined voting power; or (iv)
stockholder approval of a plan of complete liquidation or dissolution of the Company or the
consummation of an agreement for the sale or disposition of substantially all of the Company’s
assets, other than a sale or disposition to an entity, more than 50% of the combined voting
power of which is owned by the Company’s stockholders in substantially the same proportions
as their ownership of the Company immediately prior to such sale or a sale or disposition
to an entity controlled by the Company’s Board. However, a Change in Control will not
be deemed to have occurred as a result of any transaction or series of integrated transactions
following which the Company’s stockholders, immediately prior thereto, hold immediately
afterward the same proportionate equity interests in the entity that owns all or substantially
all of the Company’s assets. |
v3.23.3
Cover
|
Sep. 21, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 21, 2023
|
Entity File Number |
001-38861
|
Entity Registrant Name |
GUARDION
HEALTH SCIENCES, INC.
|
Entity Central Index Key |
0001642375
|
Entity Tax Identification Number |
47-4428421
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2925
Richmond Avenue
|
Entity Address, Address Line Two |
Suite 1200
|
Entity Address, City or Town |
Houston
|
Entity Address, State or Province |
TX
|
Entity Address, Postal Zip Code |
77098
|
City Area Code |
(800)
|
Local Phone Number |
873-5141
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
Trading Symbol |
GHSI
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2024 to May 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From May 2023 to May 2024